Pfizer Inc. $PFE Shares Sold by Destination Wealth Management

Destination Wealth Management lessened its holdings in Pfizer Inc. (NYSE:PFE) by 4.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 817,906 shares of the biopharmaceutical company’s stock after selling 42,356 shares during the quarter. Destination Wealth Management’s holdings in Pfizer were worth $20,366,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Horizon Financial Services LLC boosted its holdings in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the fourth quarter valued at $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer during the fourth quarter valued at $28,000. HFM Investment Advisors LLC boosted its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the second quarter valued at $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $26.19 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company’s 50-day moving average price is $26.43 and its two-hundred day moving average price is $26.32. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The stock has a market cap of $149.26 billion, a PE ratio of 19.99 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the business earned $0.92 earnings per share. Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date was Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s payout ratio is 131.30%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. UBS Group restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Citigroup lifted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.